Bildkälla: Stockfoto

Sedana Medical Q4: Beat us on sales and seems to return to acceleration - Redeye

Redeye notes that Sedana Medical’s Q4 report showed higher sales than our estimates, though EBITDA was fairly in line with our expectations. We believe Sedana Medical stands a chance to make a considerable return to growth during 2024, which could better point to its likelihood of success in the future US launch.

Redeye notes that Sedana Medical’s Q4 report showed higher sales than our estimates, though EBITDA was fairly in line with our expectations. We believe Sedana Medical stands a chance to make a considerable return to growth during 2024, which could better point to its likelihood of success in the future US launch.
Börsvärldens nyhetsbrev
ANNONSER